# COVID-19

## ANTIBODY TESTING

ELECSYS® ANTI-SARS-COV-2
ROCHE DIAGNOSTICS



Elecsys® Anti-SARS-CoV-2 is an immunoassay intended for qualitative detection of antibodies to SARS-CoV-2 in human serum and plasma (K2-EDTA, K3-EDTA, Li-heparin).

The test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.

Spokane Area Patient Lab Locations:

21950 E. Country Vista Dr. | Suite 200
509.309.3834

12615 E. Mission Ave. | Suite 108
509.473.9952

318 E. Rowan | Suite 205
509.473.9185

1307 S. Grand Blvd.
509.808.2614

105 W. Prairie Shopping Center
208.719.7999

## ABOUT ELECSYS ANTI-SARS-COV-2 SEROLOGY TEST

- The serology test has a specificity greater than 99.8% and sensitivity of 100% (14 Days post-PCR confirmation)

Elecsys® Anti-SARS-CoV-2 is an immunoassay for the in-vitro qualitative detection of antibodies (IgG and IgM) to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in human serum and plasma. Presence of antibodies indicates recent or prior SARS-CoV-2 infection and may indicate protection from getting re-infected however how much protection and how long that protection may last are currently unknown. Patients with PCR-confirmed infection who present subclinically may not produce measurable levels of antibodies. Testing for antibodies should not be used for acute SARS-CoV-2 infection; follow-up testing with a molecular diagnostic assay is recommended.

The Elecsys® Anti-SARS-CoV-2 assay has 99.81% specificity and shows no cross-reactivity to the four human coronaviruses known to cause the common cold based on data from over 5000 patient samples. The high specificity of this test helps to rule out antibodies to non-SARS-CoV-2 viruses that would cause false positive results. Elecsys® Anti-SARS-CoV-2 detected antibodies with 100% sensitivity in samples taken 14 days after a PCR-confirmed infection. The specificity and sensitivity of a particular test will be dependent on timing of collection during a patient's disease course and disease prevalence within a given population.

The United States FDA has made this test available under an emergency access mechanism called an Emergency Use Authorization (EUA).

incyte DIAGNOSTICS